ArticleCancer science2023
Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1
Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Targeting AKR1C1 overcomes lenvatinib resistance in hepatocellular carcinoma through the STAT3-ABC transporters pathway.Journal of gastrointestinal oncology · 2026Article
- Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma.Clinics (Sao Paulo, Brazil) · 2026Article
- Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer.Cancer cell international · 2026Review
- Aberrant VEGFR2 supports tumor growth by extracellular matrix remodeling.Cell death & disease · 2026Article
- Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.Frontiers in immunology · 2026Article
- Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.BMC cancer · 2025Article
- Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2025Article
- Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy.Journal of hematology & oncology · 2025Review
- Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma.Discover oncology · 2025Article
- Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab.Gynecologic oncology reports · 2025Article
- Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway.Apoptosis : an international journal on programmed cell death · 2025Article
- Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study.Investigational new drugs · 2025Article
- Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.Frontiers in immunology · 2025Article
- Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.Journal of hematology & oncology · 2024Review
- Exploiting temporal aspects of cancer immunotherapy.Nature reviews. Cancer · 2024Review
- Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1Cancer science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.